Granules India counts peptide CDMO among its next growth pillars
Management frames FY26 as the start of a new cycle after roughly three years of flat performance at the generics maker.
TR
By Tom Reyes · Markets Editor
Sep 30 00:58 ETSource: Business Upturn
The wire
- 01Granules India says it is shifting from high-volume generics toward controlled substances, complex generics, oncology and a peptide contract development and manufacturing business.
- 02Peptide CDMO capacity in India is one supply route for makers of peptide APIs, so buyers and formulators may watch where Granules adds capability.
- 03The company describes the plan as the beginning of a growth cycle; no peptide-specific capacity, customer or revenue figures were disclosed in the report.
From the source
Read at businessupturn.comGranules India 2.0: Controlled substances, complex generics, oncology and peptide CDMO set up the next growth cycle
Granules India is trying to move beyond the identity of a high-volume, cost-efficient generic drug manufacturer. After nearly three years of relatively flat performance, management says FY26 marked the beginning of a new growth cycle built around differentiated products, stronger R&D economics and higher-value businesses.
